Date prepared: July 15, 2021
Time: 2:53 pm
Abbreviated name of the issuer: CELON PHARMA S.A.
Allocation of D-series shares
Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) – confidential information.
Content of the report:
to current report 29/2021 of June 25, 2021 on the Resolution of the Management Board Celon Pharma S.A. (“Company”) on the share capital increase under the authorized capital, the Management Board of the Company informs that on July 15, 2021 it allocated 6,000,000 ordinary D-series bearer shares with the nominal value of PLN 0.10 each. The required cash contributions have been made in full by everyone taking up the above-mentioned D-series shares. The issue price of the D-series shares amounted to PLN 36 per share.
D-series shares will be subject to the Company's application for admission and introduction to trading on the regulated market operated by the Warsaw Stock Exchange. The Management Board of the Company wishes to underline that, as indicated in the Update Announcement No. 1 of July 1, 2021 of the prospectus of Celon Pharma S.A. approved on 1 July 2021 by the Polish Financial Supervision Authority [KNF] ("Prospectus"), pursuant to the Underwriting Agreement, the Company and Glatton sp. z o.o., which is the Company's majority shareholder, made commitments with the Global Co-ordinators listed in the Prospectus, which restrict, inter alia, the ability of such entities to offer, dispose of or encumber the Company's shares until the lapse of 365 days after the date of the first listing of the Company's Offered Shares on the Warsaw Stock Exchange, on the terms and conditions specified in the Prospectus in chapter "Underwriting of the Offer, lack of financial stability and contractual restrictions on the marketability of shares” in point “Contractual restrictions on the marketability of Shares".